Darlifarnib - Kura Oncology
Alternative Names: KO-2806Latest Information Update: 10 Sep 2025
At a glance
- Originator Kura Oncology
- Class Antineoplastics; Small molecules
- Mechanism of Action Farnesyltranstransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Adenocarcinoma; Colorectal cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
Most Recent Events
- 10 Sep 2025 Phase-I clinical trials in Colorectal cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO)
- 26 Aug 2025 Chemical structure information added.
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Renal cell carcinoma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)